A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Why Intellia Therapeutics (NTLA) Is On Investors' Radar Intellia Therapeutics (NTLA) has drawn attention after a recent stretch of positive returns, with the stock up over the month, the past 3 months, and over the past year. For investors, this performance is sitting alongside a business that reports US$67.671 million in revenue and a net loss of US$412.694 million, reflecting the costs of its clinical stage gene editing programs and partnership agreements. See our latest analysis for Intellia Therapeutics. At a share price of US$13.82, Intellia's recent 41.89% 3 month share price return and 50.05% year to date share price return contrast with a 65.66% decline in total shareholder return over three years. This signals that momentum has picked up recently while longer term holders have experienced weaker outcomes. If Intellia's recent rebound has caught your
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics (NTLA) was upgraded by JonesTrading from "hold" to "buy". They now have a $29.00 price target on the stock.MarketBeat
- Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.MarketBeat
- Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..MarketBeat
- Intellia Therapeutics (NTLA) had its price target raised by Leerink Partners from $27.00 to $29.00. They now have an "outperform" rating on the stock.MarketBeat
- Intellia Therapeutics (NTLA) had its price target raised by Royal Bank Of Canada from $9.00 to $15.00. They now have a "sector perform" rating on the stock.MarketBeat
NTLA
Earnings
- 2/26/26 - Beat
NTLA
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- NTLA's page on the SEC website